*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined. NUCALA is indicated for the add-on treatment of patients 6+ with severe eosinophilic asthma (SEA). Not for acute bronchospasm or status asthmaticus....
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016;4:549-56.Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with...
Let’s get to it withNUCALA. NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. Learn about taking NUCALA at home Info about NUCALA sent straight to my inbox? Sign me up. ...
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study doi:10.2147/JAA.S437190NASAL polypsASTHMATICSASTHMASINUSITISSCIENTIFIC observationCOMORBIDITYObjective of this study was to assess NP and asthma outcomes...
The present study investigated the characteristics of EETs from patients with non-severe asthma (NSA, n = 20) and severe eosinophilic asthma (SEA, n = 20) and evaluated EET function. The percentage of EET-forming peripheral blood eosinophils stimulated with IL-5 and LPS was ...
Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous
Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. Funding GlaxoSmithKline. Introduction Severe asthma is associated with substantial morbidity, mortality, and health-care costs.1Recurrent asthma exacerbations are...
其中,對於專門針對免疫球蛋白 E(IgE)所導致的哮喘,或是以嗜酸性粒細胞抗體(Anti-eosinophilic antibody)針對因嗜酸性粒細胞過多而引起的哮喘6, 患者可定時接受相關皮下注射藥物9,以減低發作機會,達致緩解病情。不過, 部分病人在治療期間可能會出現注射部位不適及角膜炎等問題10。